SER (Serina Therapeutics Inc.) stock: $1.38, $34.9M market cap, $29.4M cash, $5.5M EV, $47.6M fully diluted market cap. Next expected readout: Jan-27. Lead program: SER-252 (PEOZ-apomorphine) (PARKINSON DISEASE (Disorder)), Phase 1. Data from Fully Diluted's biotech stocks database.
What they do
We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Lead product candidate; POZ-modified apomorphine. FDA cleared IND Jan 2026; Phase 1b registrational study in advanced Parkinson's disease initiated with first patient dosed Feb 2026.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.